Sort   by:  
 Page size 
TranscriptomicsBT474 and BT474-J4 microarray data
These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to test the combination of HER2-targeted agents and GSK1363089 (foretinib) in the clinic by using an acquired lapatinib-resistant cell line. Cell lines (BT474, an HER...
ORGANISM(S): Homo sapiens 
2011-09-19 | E-GEOD-16179 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of lapatinib treated of breast cancer cell lines
Dose and time course response of lapatinib in breast cancer cell lines.
ORGANISM(S): Homo sapiens 
2005-10-15 | E-MEXP-440 | biostudies-arrayexpress
TranscriptomicsGenome-wide DNA copy number predictors of lapatinib sensitivity in tumour-derived cell lines
A common aim of pharmacogenomic studies that employ genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous investigations of lapatinib, a selective dual-kinase inhibitor of EGFR and HER2 tyrosine...
ORGANISM(S): Homo sapiens 
2008-03-10 | E-GEOD-9585 | biostudies-arrayexpress
TranscriptomicsHuman breast cancer cells: parental v.s lapatinib-resistant clone
Transcriptional profiling of human HER2-positive BT474 breast cancer cells comparing control untreated cancer cells with lapatinib-resistant clone established by chronic treatment with lapatinib Two-condition experiment, parental cells vs. lapatinib-resistant (LR) clone.
ORGANISM(S): Homo sapiens 
2013-10-31 | E-GEOD-51889 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal
To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant'...
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10314 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib
To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10304 | biostudies-arrayexpress
ProteomicsLapatinib-Induced Enhancement Of Mitochondrial Respiration In HER2-Positive SK-BR-3 Cells: Mechanism Revealed By Analysis Of Proteomic But Not Transcriptomic Data
Dual inhibitors of HER2 and EGFR, such as lapatinib, have shown significant efficacy for the therapy of HER2-positive breast cancer. Previous experiments showed that in cell cultures, the efficacy of lapatinib was significantly reduced by exposure to human serum and human epidermal growth factor (EG...
ORGANISM(S): Homo sapiens (Human) 
2024-09-26 | PXD054180 | Pride
Proteomics Squamous cell carcinoma sk-br-3 Her-targeted cancer therapy Drug resistance Tricarboxylic acid cycle tca Human blood serum Cellular respiration Lapatinib 
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma KYAE1 cell line treated with lapatinib
To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on KYAE1 cells treated with 500 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10310 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma WTSI-OESO_009 (CAM408) organoid treated with lapatinib
To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on WTSI-OESO_009 cells treated with 1000 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10306 | biostudies-arrayexpress
TranscriptomicsATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib
To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.
ORGANISM(S): Homo sapiens 
2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress
Sort   by:  
 Page size